Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2010 - 2025)

Sonoma Pharmaceuticals' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $2.6 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 51.09% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (down 51.09% YoY), while the FY2025 annual figure was $5.4 million, up 71.8% from the prior year.
• Cash & Equivalents was $2.6 million for Q4 2025 at Sonoma Pharmaceuticals, down from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.5 million in Q4 2021 to a low of $2.1 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $4.2 million across 5 years, with a median of $3.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 69.12% in 2022, then surged 117.62% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $8.5 million in 2021, then sank by 69.12% to $2.6 million in 2022, then retreated by 8.66% to $2.4 million in 2023, then soared by 117.62% to $5.2 million in 2024, then sank by 51.09% to $2.6 million in 2025.
• The last three Cash & Equivalents figures came in at $2.6 million (Q4 2025), $3.0 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.